LILLY LINKS WITH SPHINX: $72 MIL. PROPOSED BUYOUT
LILLY LINKS WITH SPHINX: $72 MIL. PROPOSED BUYOUT announced by the two companies March 8 would make Sphinx Pharmaceuticals a wholly-owned subsidiary of Lilly. A letter of intent signed by the two firms calls for Lilly to pay $6 per share for the 12 mil. outstanding shares of Sphinx stock, excluding the 680,000 shares bought by Lilly for $4 mil. in October 1991. The initial equity investment was part of a collaborative research agreement focused on developing protein kinase C regulators. The proposed purchase is subject to the signing of a definitive agreement and approval by Sphinx shareholders.
You may also be interested in...
The Elan market meltdown is likely to shut off the joint venture route as one avenue for struggling biotech companies to obtain capital
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011